Skip to main content

Table 1 Patients’ characteristics

From: Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed

  N pts %
Gender
  Female 11 44
  Male 14 56
Age
  <60 13 52
  > r =60 12 48
ECOG
  0 9 36
  1 15 60
  2 1 4
Tobacco
  Current smoker 4 16
  Never smoker 7 28
  Former smoker 14 56
Histology
  Adenocarcinoma 22 88
  Adenocarcinoma poorly differentiated 2 8
  Adeno-squamous 1 4
T
  T1-2 12 48
  T3-4 13 52
N
  N0 6 24
  N+ 19 76
M
  M0 7 28
  M1 18 72
Lung metastases
  Presence 7 28
  Absence 18 72
Liver metastases
  Presence 2 8
  Absence 23 92
Bone metastases
  Presence 10 40
  Absence 15 60
Brain metastases
  Presence 8 32
  Absence 17 68
EGFR
  Wild type 23 92
  Mutant 1 4
  Unknown 1 4
Line of treatment
  First/Induction (stage III) 2 8
  First 21 84
  Second 1 4
  Third 1 4
Response
  Response 18 72
  Progression + Stabilization 7 28
Maintenance
  No maintenance 18 72
  Maintenance 7 28
Progression
  Not progressed 6 24
  Progressed 19 76
Clinical status
  Alive 12 48
  Dead 13 52
  1. Eastern Cooperative Oncology Group (ECOG). Epidermal Growth Factor Receptor (EGFR).